Eisai (4523.T) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Eisai, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track 4523.T live on Mooboard →

Later9

  • Dec 3, 2026
    Eisai(4523.T)Phase 2/3 readout
    E2814 · Phase 2 · Alzheimer's Disease
    NCT06602258: A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease. Primary completion 2026-12-03 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 14, 2027
    Eisai(4523.T)Phase 2/3 readout
    E2086 · Phase 2 · Narcolepsy
    NCT07493265: A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy. Primary completion 2027-02-14 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 31, 2027
    Eisai(4523.T)Phase 2/3 readout
    E7386 · Phase 1 / Phase 2 · Endometrial Neoplasms; Neoplasms
    NCT04008797: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor. Primary completion 2027-03-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 31, 2027
    Eisai(4523.T)Phase 2/3 readout
    E7389-LF · Phase 1 / Phase 2 · Solid Neoplasms
    NCT04078295: A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor. Primary completion 2027-03-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 6, 2027
    Eisai(4523.T)Phase 2/3 readout
    Perampanel Oral Suspension · Phase 2 · Pediatric Epileptic Syndrome; Partial-onset Seizures
    NCT04015141: A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy. Primary completion 2027-04-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 5, 2028
    Eisai(4523.T)Phase 2/3 readout
    E6742 · Phase 2 · Systemic Lupus Erythematosus
    NCT07515014: A Study of E6742 in Participants With Systemic Lupus Erythematosus. Primary completion 2028-08-05 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 21, 2028
    Eisai(4523.T)Phase 2/3 readout
    Lecanemab · Phase 3 · Preclinical Alzheimer's Disease; Early Preclinical Alzheimer's Disease
    NCT04468659: AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid. Primary completion 2028-12-21 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2029
    Eisai(4523.T)Phase 2/3 readout
    Lecanemab IV · Phase 3 · Early Alzheimer's Disease
    NCT03887455: A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease. Primary completion 2029-06-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 8, 2030
    Eisai(4523.T)Phase 2/3 readout
    Farletuzumab ecteribulin · Phase 1 / Phase 2 · Solid Tumor
    NCT04300556: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types. Primary completion 2030-08-08 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Eisai has moved — past-year price reactions

How binary is 4523.T? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.3%
typical day (1Y)
0
±10% days
30.9%
annualized vol
242
trading days
Largest single-day moves
  • +7.4%2025-11-25no matched headline
  • +6.7%2026-07-29no matched headline
  • -6.2%2026-05-18no matched headline
  • +6%2026-02-10no matched headline
  • +5%2026-04-01no matched headline
  • -4.9%2026-05-20no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Eisai — active clinical pipeline

Eisai's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

14 assets18 programsPh1 7Ph2 7Ph3 3· 1 post-marketing (Ph4)
AreasOncologyAutoimmuneNeuroscienceInfectiousOther
LecanemabNeuroscience · amyloid-β
Phase 3
Preclinical Alzheimer's Disease
Lecanemab IVNeuroscience
Phase 3
Early Alzheimer's Disease
LenvatinibOncology
Phase 3
Renal Cell Carcinoma
E7386Oncology
Phase 1
Advanced NeoplasmsSolid Neoplasms
Phase 2
Endometrial Neoplasms
E2086Neuroscience
Phase 1
Neuroscience
Phase 2
Narcolepsy
E7389-LFOncology
Phase 1
Solid Tumor
Phase 2
Solid Neoplasms
E2814Neuroscience
Phase 2
Alzheimer's Disease
E6742Autoimmune
Phase 2
Systemic Lupus Erythematosus
Farletuzumab ecteribulinOncology
Phase 2
Solid Tumor
Perampanel Oral SuspensionNeuroscience
Phase 2
Pediatric Epileptic Syndrome
E1018Infectious
Phase 1
Malaria
Palbociclib (75, 100, 125 milligram [mg])Other · CCND1/CDK4
Phase 1
Receptors, Estrogen
TasurgratinibOther · FGFR1/2/3
Phase 1
Hepatic Impairment

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.